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Abstract
Background: Parasites incur periodic mutations which must ultimately be eliminated to maintain
their genetic integrity.
Methods: It is hypothesised that these mutations are eliminated not by the conventional
mechanisms of competition between parasites in different hosts but primarily by competition
between parasites within the same infection.
Results: This process is enhanced by the production of a large number of parasites within
individual infections, and this may significantly contribute to parasitic virulence.
Conclusions: Several features of the most virulent human malaria parasite Plasmodium falciparum
can usefully be re-interpreted in this light and lend support to this interpretation. More generally,
it constitutes a novel explanation for the evolution of virulence in a wider range of microparasites.
Background
Why are some parasites so virulent? This is one of the key
questions in the extension of evolutionary thinking into
medical sciences (for a recent access to the empirical and
theoretical literature, see Refs [1,2]). There are several
plausible explanations for virulence. One is that a certain
degree of virulence is beneficial to the organism: a human
rendered prone by a malaria fever is less likely to move
and kill the mosquitoes which feed on him and spread the
infection; the diarrhoea associated with cholera may
result in more widespread transmission of the disease,
and so on. Occasional host mortality is regrettable from
all points of view because host mortality generally also
kills the parasite, but is explicable as it occurs at one end
of a spectrum of disease states. A second explanation for
virulence is that a high parasitaemia causes host pathol-
ogy but concomitantly results in more assured transmis-
sion of the parasite. According to this hypothesis the
observed level of virulence is a "trade-off" between mini-
mising host mortality and maximising transmission. [This
argument is appropriate to P. falciparum despite the obser-
vation that some people with high parasitaemia show no
symptoms while some exhibit severe disease with far
fewer parasites, most probably as a consequence of differ-
ing levels of immunity; the key argument is that all other
things being equal, higher parasitaemia tends to produce
more severe disease, an assertion that seems reasonable
for P. falciparum]. These two explanations both assume a
degree of evolutionary fine-tuning to achieve an optimal
level of virulence. There are two other explanations for vir-
ulence that rest not on evolutionary trade-offs but purely
on bad luck. If an infection consists of millions or billions
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mutation may occur that grows rapidly, comes to domi-
nate the infection and can cause a pathology which is det-
rimental for both host and parasite. Alternately, virulence
can occur when a parasite finds itself in an exotic host spe-
cies to which it is not adapted; the most familiar examples
are human zoonosis such as Lassa fever or Ebola. Here we
present a novel, fifth reason why virulence may occur. Like
the first two hypotheses, it rests on an evolutionary, rather
than bad-luck, argument. Moreover, it explains several
puzzling features of the biology of Plasmodium falciparum,
the organism responsible for the most severe form of
human malaria.
Many severe human infections are characterised by a large
number of individual parasites that acutely infect a host
for a relatively short time before being eradicated by host
immunity. Central to our thesis is a consideration of how
deleterious mutations (for example, those disrupting pro-
tein structure and general cellular machinery) are elimi-
nated during the life cycles of these organisms. In
conventional evolutionary thinking, deleterious muta-
tions are eliminated by direct competition with individu-
als carrying the normal non-mutated wildtype gene. Thus,
for example, a mutation decreasing flight efficiency in a
mosquito would ultimately be eliminated through being
out-competed by mosquitoes with competent flight phys-
iology. This type of mutation elimination is termed "puri-
fying selection" and prevents mutations establishing
themselves in the gene pool of the organisms. The prob-
lem is that populations of parasites such as malaria are
highly sub-divided into numerous separate human hosts
and face the overwhelming selective pressure of host
immunity. Direct competition between separate clones of
malaria in different hosts will be small and purifying
selection correspondingly weak. ['Clones' is used here to
denote the large number of parasites in a human
descended from a single inoculated sporozoite. People in
highly endemic areas may contain up to seven distinct
clones, derived from separate infective bites, a feature
quantified as their 'clonal multiplicity'. Critically, 'clones'
does not imply that they are genetically stable over time,
more realistically they are transitory and broken down
during meiosis in the obligate sexual phase of the P. falci-
parum life cycle]. Our central argument is that mutations
in this type of life history may be nullified by compensa-
tory mutation rather than being eliminated by purifying
selection. This occurs when a second "compensatory"
mutation occurs within the gene which restores the meta-
bolic activity of the gene product and hence nullifies the
effect of the original mutation. There are two lines of evi-
dence supporting this hypothesis. Firstly, the patterns of
molecular evolution observed in P. falciparum and, in par-
ticular, the rapid rate of non-synonymous (i.e. protein
altering) mutations are consistent with their being com-
pensatory. Secondly, compensatory mutations are noted
in laboratory populations of organisms kept in isolation
(see later).
Methods
The efficacy of compensatory mutation depends on two
factors, the size of the parasite population within the
human host (which determines whether the rare compen-
satory mutation will actually occur within an individual
host) and the number of replication cycles in the life cycle
(which determines the extent to which the compensatory
mutation spreads within the host prior to its transmis-
sion). The stochastic element in the process means that it
is best investigated by computer simulation. The simula-
tions are used to calculate the probability that (i) a fully-
functional "wildtype" malaria infection will suffer a dele-
terious mutation and be transmitted by a mosquito as a
mutated "dysfunctional" form, and (ii) that a compensa-
tory mutation will occur in a "dysfunctional" infection
and spread within this infection to the extent that it will
be transmitted by a mosquito as the compensated, meta-
bolically functional, wildtype form. The relative magni-
tudes of the two processes determine the equilibrium
frequency of wildtype and dysfunctional malaria parasites
within the human population.
Equilibrium frequency of the fully functional wildtype form of a parasite as a consequence of the number of parasites withinthe human host (its clonal p pulation size) and number ofparasite rythrocyt  cycles (each of which sts wo days)which l pse prior to tran mission.Figure 1
Equilibrium frequency of the fully functional wildtype 
form of a parasite as a consequence of the number of 
parasites within the human host (its clonal popula-
tion size) and number of parasite erythrocyte cycles 
(each of which lasts two days) which elapse prior to 
transmission. Computational details are as described in the 
main text i.e. dysfunctional mutation rates = 10-5, beneficial 
mutation rates = 10-8, and the selective disadvantage of the 
mutation is 10% per erythrocytic cycle.
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case where the parasites consist of only two types: the fully
functional "wildtype" and a mutated "dysfunctional"
type. The latter suffers a growth disadvantage compared to
the wildtype, so are gradually eliminated if both types are
simultaneously present in the same human host. Parasites
can mutate from one type to the other. Mutations occur in
wildtype parasites converting them to the dysfunctional
type, and compensatory mutations occur in the dysfunc-
tional types restoring the gene function and thereby con-
verting them back to the wildtype form. These are referred
to as "dysfunctional" and "beneficial" mutations respec-
tively and are quantified as the rate per Plasmodium per
erythrocyte cycle. Note that dysfunctional mutations can
occur in a large number of genes, all of which periodically
mutate to the dysfunctional form. Conversely, beneficial
mutations can occur only in those few codons where a
compensatory mutation can compensate for the original
deleterious mutation. Thus, dysfunctional mutation rates
will be several orders of magnitude higher than the bene-
ficial rate. In the example shown on figure 1, these rate are
10-5 and 10-8 per erythrocytic cycle respectively, which
means that, on average, one in 100,000 wildtype plasmo-
dia mutates to a deleterious form in each erythrocyte cycle
(and similarly that 1 in 10,000,000 mutants have their
function restored each erythrocyte cycle). The key phrase
in the preceding sentence is "on average". In particular, if
the number of parasites within a host is small then zero
mutations may occur. The variation in the dynamics
between individual infections can be large, so the results
are best presented as the equilibrium frequency of the
wildtype forms in the population. The exact shape of fig-
ure 1 depends on the values of mutation rates and the
selective disadvantage of the deleterious mutation (10%
per erythrocytic cycle in this example), but the general
results are robust.
Technical aspects of the simulations are as follows. The
infection starts out as either entirely wildtype or entirely
dysfunctional type, depending on the type of sporozoite
that initiated the infection. The mean number of muta-
tions expected per cycle is calculated and the actual
number randomly drawn from a Poisson distribution
around this mean; for example, if the clonal population
size is 107 and the mutation rate is 10-8, then the program
will pick zero mutations per cycle in about 90% of
simulations, one in about 10% of simulations and two or
more in a small proportion of simulations. Once the
number of new mutations has been simulated, these are
added to the number that already exist and the next eryth-
rocytic cycle is simulated. The number of mutations in the
next cycle is also drawn from a Poisson distribution but
taking into account selective differences. For example, if
20 wildtype parasites already exist, one is added by muta-
tion, and wildtypes have a 10% growth advantage then
the number next generation is drawn from a Poisson dis-
tribution with mean (1+20) × 1.1 = 23.1, and so on for the
required number of erythrocytic cycles. The simulations
are run 10,000 times for each value of clonal population
size, so that each combination of population size and
number of erythrocytic cycles produces two parameters:
, the probability that an infection, originally wildtype,
is subsequently transmitted as the dysfunctional type, and
, the probability that an infection originally dysfunc-
tional is subsequently transmitted as wildtype. The equi-
librium frequency of the wildtype expected under this
type of mutation elimination is . This sim-
ple case assumes there are only two types of parasites,
wildtype and dysfunctional. The calculations can be easily
extended to a case where dysfunctional types may contain
1,2,3,4.... deleterious mutations. The same qualitative
results arise but at the cost of greatly increased model
complexity.
Results
A typical result is shown in figure 1 where the equilibrium
frequency of the wildtype form is shown as a function of
the parasite population size within the human host
(clonal population size) and the number of erythrocyte
cycles before transmission. Increasing the clonal popula-
tion size increases the rate at which deleterious mutations
are nullified by compensatory mutations, thereby increas-
ing the equilibrium frequency of fully functional wildtype
infections. As the clonal population size increases, a law
of diminishing returns applies and the evolutionary opti-
mal size occurs when the (short-term) risk of host mortal-
ity balances the (long-term) advantages of mutation
elimination.
Discussion
This effect can be seen in controlled laboratory experi-
ments. Burch and Chao [3] showed that increasing the
clonal population size of bacteriophages increased the
speed at which beneficial mutations accumulate. Miralles
et al. [4] presented similar data for an RNA virus. Compen-
satory mutations may be a direct reversal of the original
mutation but, more typically, they restore gene function
through another compensatory mutation at another site
within the same gene. Presumably this second mutation
restores, partially or completely, the tertiary structure of
the molecule and hence its biological activity. Several
studies [3,5-9] have demonstrated this process in E. coli
and bacteriophages. P. falciparum appears to be the only
example where the process of an advantageous mutation
occurring and spreading to dominate the infection can be
directly and easily observed. If an infection is drug sensi-
tive and the human host is treated with a drug, then the
symptoms go into remission as the majority of the
parasites are eliminated. However, a small number of par-
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drug resistance. These survive and flourish even in the
presence of drugs, so that the infection reappears shortly
afterwards ("recrudesces") as a drug-resistant strain. This
process appears to be remarkably effective: 33% of infec-
tions treated with the antimalarial drug atovaquone sub-
sequently recrudesce as a drug-resistant infection [10].
The effect is extremely dependent on the size of infection.
As an example, if a human is inoculated with a drug-sen-
sitive clone and there are 1011 parasites in the host and the
mutation rate to the drug resistant form is 10-8, then there
will be a sub-population of 103 resistant parasites. Follow-
ing drug treatment, the sensitive forms will be eliminated
and the sub-population of 103 resistant forms will expand
to dominate the infection. Needless to say, if the mutation
rate to resistance is 10-8, then infection sizes of less than
ten thousand would rarely contain the appropriate muta-
tion. Current antimalarial drug deployment strategies uti-
lise this effect by using drugs in combination. If mutation
rates to resistance are 10-8 for each drug in a two-drug mix-
ture, then even an infection of 1012 individual malaria
parasites is highly unlikely (a probability of 0.0001) to
simultaneous contain a spontaneous drug-resistant muta-
tion in each gene.
P. falciparum, in common with several other parasites,
appears to try and evade host immunity by continually
changing its immune characteristics. It does so, at least in
part, by expressing a sequence of var genes [11,12]. An
interesting consequence of the above argument is that var
switching in P. falciparum may select for increased infec-
tion load (because increased parasite numbers are
required to increase effective population size) and hence
to increased virulence. The population size illustrated in
figure 1 is best interpreted as an effective population size
[13,14]. This is a key concept in population genetic theory
and is defined as being equivalent to an idealised popula-
tion whose size does not fluctuate. Effective population
size decreases rapidly if the population goes through a
series of "bottlenecks" of small population sizes. As P. fal-
ciparum switches through its antigenic repertoire, it
appears likely that only a small portion of the population
will actually survive. As human immunity to the current
var product expressed in the infection builds up and starts
to eliminate the parasites, a small proportion will have
switched to another var gene in the repertoire to escape
immunity and expand to dominate the infection [15-17].
This lowers the effective population size considerably
below the crudely observed population size of 109 to 1011
parasites in a typical human malarial infection. For exam-
ple, if the population size is 1010 but every 10 erythrocyte
cycles goes through a bottleneck of 1000 individuals
which switch var expression, the effective size decreases to
10,000. Intuitively, it is possible to see how this impedes
the spread of a compensatory mutation through an infec-
tion: even if a compensatory mutation has occurred and is
spreading through an infection, the chances are that it has
occurred in a cell lineage that will ultimately be destroyed
by human immunity acting against its var gene expression
[18].
Conclusions
It is argued that virulence occurs as a consequence of the
large parasite density (quantified as the clonal population
size within a human) required to effectively eliminate
mutations or nullify them through compensatory muta-
tions, the evolutionary optimal level of virulence being
determined by the conflicting necessity of removing
mutations balanced against the need to minimise host
mortality. This constitutes a novel hypothesis for the evo-
lution of virulence and is a simple consequence of an
inevitable fact of life: that deleterious mutations occur
and must be effectively eliminated. It is difficult to see
how this can be done effectively solely by the actions of
the purifying selection envisaged in conventional popula-
tion genetic theory, and it appears that compensatory
mutations play a major role. P. falciparum life history traits
may, therefore, have evolved to facilitate the effective
incorporation of compensatory mutations, the most nota-
ble consequence being that they reach very high numbers
within individual hosts. Virulence may therefore be sim-
ply an unfortunate side effect of large infection sizes, par-
asites evolving to be as benign as possible while still
maintaining an infection density (clonal population size
within the human) sufficient to allow the effective
removal of deleterious mutations. The trade off between
these conflicting interests determines the optimal level of
virulence (see figure 1). The alternative hypotheses for
explaining the evolution of virulence cannot be resolved,
all being entirely plausible post-hoc explanations. How-
ever, the mutation/selection hypothesis explains three
interesting facets of the P. falciparum lifecycle. Firstly, that
the correlation between parasite load and infectivity in the
field is weak [19], suggesting that increased infectivity is a
relatively weak selective force for increased parasite load.
Secondly, that despite a large asexual parasite load, the
number of infective stages is surprisingly small [20] and
usually consists of around 5% of the total parasite
number. There are several plausible explanations for this.
For example, that they are kept at low levels by host
immunity, or are produced at low frequencies to mini-
mise their stimulation of host immunity, or that low lev-
els avoid damaging the mosquito vector.
These explanations are immaterial to our argument which
addresses the issue of trying to understand why 95% of
the parasites which, moreover, are the ones responsible
for clinical disease and host death, are necessary to pro-
duce the remaining 5% of infective stages. The
explanation proposed here is that this 95% constitutes aPage 4 of 5
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large selective environment ensuring that the subsequent
infective stages harbour a minimal number of deleterious
mutations. Thirdly, the conventional hypothesis that
increasing parasite load increases transmissibility does
not explain why the turnover of parasites is so high (espe-
cially because, as noted above, gametocytes are present at
a low level and are relatively long-lived), whereas our
analysis of mutation elimination demonstrates that
increasing turnover of parasites increases the rate at which
compensatory mutations spread (figure 1).
These arguments have been developed with specific refer-
ence to the human malaria parasite P. falciparum. The
same line of argument applies to many other infective
agents. Many parasitic protozoa, bacteria and viruses also
build up to huge infection levels. Conventionally this has
been interpreted as a strategy to increase infectivity, but it
can just as validly be regarded as a strategy to increase the
efficacy of eliminating harmful mutations. The argument
here is not that increasing parasite load does not increase
transmissibility (it seems plausible that it does to some
extent), but that the primary function of a large, rapidly
dividing parasite population is to eliminate mutations
rather than increase transmission and that it is rewarding
to re-examine several facets of P. falciparum biology, and
presumably the biology of similar organisms, in the light
of this hypothesis.
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